Gilberto Lopes

12.6k total citations · 1 hit paper
221 papers, 3.7k citations indexed

About

Gilberto Lopes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Gilberto Lopes has authored 221 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 94 papers in Pulmonary and Respiratory Medicine and 50 papers in Economics and Econometrics. Recurrent topics in Gilberto Lopes's work include Lung Cancer Treatments and Mutations (68 papers), Economic and Financial Impacts of Cancer (37 papers) and Colorectal Cancer Treatments and Studies (36 papers). Gilberto Lopes is often cited by papers focused on Lung Cancer Treatments and Mutations (68 papers), Economic and Financial Impacts of Cancer (37 papers) and Colorectal Cancer Treatments and Studies (36 papers). Gilberto Lopes collaborates with scholars based in United States, Brazil and Singapore. Gilberto Lopes's co-authors include Benjamin Haaland, Pedro Nazareth Aguiar, Pui San Tan, Alberto J. Montero, Hakaru Tadokoro, Ramon Andrade de Mello, Geoffrey Y. Ku, Stefan Glück, Carlos H. Barrios and Gilberto de Castro and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gilberto Lopes

204 papers receiving 3.6k citations

Hit Papers

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
    2022 151 citations Gilberto de Castro, Gilberto Lopes et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gilberto Lopes United States 35 2.2k 1.5k 607 538 482 221 3.7k
Paul G. Kluetz United States 34 1.8k 0.8× 1.3k 0.8× 608 1.0× 579 1.1× 671 1.4× 174 4.0k
Dario Trapani Italy 31 2.2k 1.0× 1.2k 0.8× 977 1.6× 921 1.7× 389 0.8× 201 4.3k
Julia A. Beaver United States 39 2.7k 1.2× 1.5k 1.0× 1.1k 1.8× 1.1k 2.1× 464 1.0× 131 4.8k
Narjust Duma United States 18 1.6k 0.7× 1.2k 0.8× 594 1.0× 809 1.5× 207 0.4× 95 3.3k
Masashi Ando Japan 31 2.0k 0.9× 954 0.6× 774 1.3× 688 1.3× 168 0.3× 206 3.6k
Roman Gulati United States 34 1.6k 0.7× 2.3k 1.5× 662 1.1× 672 1.2× 236 0.5× 128 3.6k
Blasé N. Polite United States 32 3.3k 1.5× 1.1k 0.8× 654 1.1× 733 1.4× 433 0.9× 164 4.9k
Jonathan M. Loree Canada 31 2.2k 1.0× 877 0.6× 921 1.5× 745 1.4× 252 0.5× 177 3.7k
Alicia K. Morgans United States 29 1.1k 0.5× 1.9k 1.3× 429 0.7× 557 1.0× 236 0.5× 202 3.4k
Jean-Yves Douillard France 29 3.1k 1.4× 3.1k 2.1× 850 1.4× 942 1.8× 373 0.8× 70 5.7k

Countries citing papers authored by Gilberto Lopes

Since Specialization
Citations

This map shows the geographic impact of Gilberto Lopes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilberto Lopes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilberto Lopes more than expected).

Fields of papers citing papers by Gilberto Lopes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilberto Lopes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilberto Lopes. The network helps show where Gilberto Lopes may publish in the future.

Co-authorship network of co-authors of Gilberto Lopes

This figure shows the co-authorship network connecting the top 25 collaborators of Gilberto Lopes. A scholar is included among the top collaborators of Gilberto Lopes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilberto Lopes. Gilberto Lopes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ichim, Thomas E., Gilberto Lopes, Boris Minev, et al.. (2025). Reduction of solid tumors by senescent cell immunization. Journal of Translational Medicine. 23(1). 1365–1365.
2.
Samol, Jens, Jonathan Poh, Min-Han Tan, et al.. (2025). Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK). JCO Precision Oncology. 9(9). e2500181–e2500181. 4 indexed citations
3.
Yu, Qian, Fan Cao, Peter J. Hosein, et al.. (2025). Dethroning of Neuroendocrine Tumor as an Orphan Disease: US Incidence, Prevalence, and Survival in the 21st Century. Cancers. 17(20). 3323–3323. 1 indexed citations
4.
Schram, Alison M., Gilberto Lopes, Elisa Fontana, et al.. (2024). 691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation. Annals of Oncology. 35. S535–S536. 2 indexed citations
5.
Elliott, Andrew, Wendy Cozen, Evanthia T. Roussos Torres, et al.. (2024). Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8526–8526. 1 indexed citations
6.
Elliott, Andrew, Stephen V. Liu, C. Patrick, et al.. (2024). A pan-tumor description of the genomic, transcriptomic, and immunological landscape of sodium-glucose cotransporter-2 (SGLT2) and association with clinical outcomes.. Journal of Clinical Oncology. 42(23_suppl). 104–104. 1 indexed citations
7.
Trabolsi, Asaad, Estelamari Rodríguez, Jennifer R. Ribeiro, et al.. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist. 29(11). e1480–e1491. 7 indexed citations
8.
Schwartsmann, Gilberto, et al.. (2024). Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis. Diabetes Obesity and Metabolism. 26(5). 1929–1940. 8 indexed citations
9.
Medina, Heidy N., Estelamari Rodríguez, Clyde Brown, et al.. (2024). Trends and Disparities in Curative-Intent Treatment for Early-Stage Non–Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT. Cancer Epidemiology Biomarkers & Prevention. 33(4). 489–499. 4 indexed citations
10.
11.
Razi, Syed S., Jinmeng Rao, Gilberto Lopes, et al.. (2023). Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma. JAMA Network Open. 6(3). e234261–e234261. 11 indexed citations
12.
O’Neil, Daniel S., Yehoda M. Martei, Katherine D. Crew, et al.. (2023). Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Network Open. 6(12). e2346223–e2346223. 1 indexed citations
13.
Lopes, Gilberto, et al.. (2023). Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice. 198. 110621–110621. 35 indexed citations
14.
Barrios, Carlos H., Gilberto Lopes, Mastura Md Yusof, et al.. (2022). Barriers in access to oncology drugs — a global crisis. Nature Reviews Clinical Oncology. 20(1). 7–15. 60 indexed citations
15.
16.
Morgan, Gilberto, Evandro de Azambuja, Kevin Punie, et al.. (2021). OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Global Oncology. 7(7). 455–463. 6 indexed citations
17.
Aguiar, Pedro Nazareth, Felipe Roitberg, Gilberto Lopes, & Auro del Giglio. (2020). Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System. Jornal Brasileiro de Pneumologia. 46(4). e20180255–e20180255. 1 indexed citations
18.
Gralow, Julie R., Fredrick Chite Asirwa, Ami S. Bhatt, et al.. (2020). Recommendations from the ASCO Academic Global Oncology Task Force. JCO Global Oncology. 6(6). 1666–1673. 11 indexed citations
19.
20.
Araujo, Luiz H., Clarissa Baldotto, Gilberto de Castro, et al.. (2018). Lung cancer in Brazil. Jornal Brasileiro de Pneumologia. 44(1). 55–64. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul G. Kluetz Breakdown of academic impact, for papers by Dario Trapani Breakdown of academic impact, for papers by Julia A. Beaver Breakdown of academic impact, for papers by Narjust Duma Breakdown of academic impact, for papers by Masashi Ando Breakdown of academic impact, for papers by Roman Gulati Breakdown of academic impact, for papers by Blasé N. Polite Breakdown of academic impact, for papers by Jonathan M. Loree Breakdown of academic impact, for papers by Alicia K. Morgans Breakdown of academic impact, for papers by Jean-Yves Douillard
Rankless by CCL
2026